A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

NCT04458272 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

WHO Grade II Glioma

Interventions

DRUG: DS-1001b

Sponsor

Daiichi Sankyo Co., Ltd.